Trial: 202008099

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Phase

III (Cancer Control)

Principal Investigator

Ansstas, George

Disease Site

Melanoma, Skin

Learn more about this study at: clinicaltrials.gov